
Bristol Myers Squibb
OrganizationHeard in 58 episodes across 22 shows since Sep 2025
Bristol Myers Squibb is a publicly traded American multinational pharmaceutical company headquartered in New Jersey. It discovers, develops, manufactures, and commercializes medicines, with major businesses in oncology, cardiovascular disease, and immunology; the podcast references primarily discuss its cancer treatments, partnerships, and stock performance.
Episodes
This week
Expert statements
Share of the conversation
Mentions of Bristol Myers Squibb per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Aug 31 | 0.01‰ | 1 |
| Sep 1 | 0.02‰ | 1 |
| Sep 4 | 0.03‰ | 1 |
| Sep 13 | 0.01‰ | 1 |
| Sep 23 | 0.01‰ | 1 |
| Sep 30 | 0.01‰ | 1 |
| Oct 6 | 0.02‰ | 1 |
| Oct 8 | 0.02‰ | 1 |
| Oct 10 | 0.03‰ | 1 |
| Oct 12 | 0.07‰ | 5 |
| Oct 13 | 0.07‰ | 1 |
| Oct 15 | 0.07‰ | 1 |
| Oct 16 | 0.08‰ | 1 |
| Oct 19 | 0.03‰ | 1 |
| Oct 22 | 0.03‰ | 2 |
| Oct 26 | 0.03‰ | 2 |
| Oct 28 | 0.04‰ | 1 |
| Oct 29 | 0.03‰ | 1 |
| Oct 30 | 0.04‰ | 1 |
| Nov 2 | 0.03‰ | 1 |
| Nov 4 | 0.03‰ | 1 |
| Nov 6 | 0.02‰ | 1 |
| Nov 9 | 0.02‰ | 1 |
| Nov 20 | 0.02‰ | 2 |
Email alert
Email me when Bristol Myers Squibb comes up on a podcast
One email a week at most, with the new episodes that mention Bristol Myers Squibb. Free, no account needed, unsubscribe in one click.
What experts have said about Bristol Myers Squibb
12 statements · 8 positive · 4 negative
Bristol Myers trades at a 15% discount to Morningstar’s valuation.
“Bristol Myers stock is currently rated four stars, trades at a 15% discount”
Open the episode · 4 Stocks to Buy for the Long-Term While They’re Still UndervaluedListen at 32:42
Bristol Myers earnings are expected to rebound from 2030 onward.
“it will start to rebound in 2030 and thereafter”
Open the episode · 4 Stocks to Buy for the Long-Term While They’re Still UndervaluedListen at 35:23
The FDA is likely to approve Bristol’s IPF drug.
“it's hard to see that the FDA wouldn't approve this.”
Open the episode · Episode 199 - October 16, 2026Listen at 30:07
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
58 episodes featuring Bristol Myers Squibb, newest first
- Nov 20, 2026
Tempus bets cancer data can become an AI growth engineAfter EarningsNov 20, 2026 - Nov 20, 2026
FDA leadership falters as China biotech reshapes drug competitionThe Readout LoudNov 20, 2026 - Nov 13, 2026
Biotech launches expose the gap between forecasts and adoptionBiotech HangoutNov 13, 2026 - Nov 9, 2026
Biotech investors weigh obesity, RAS drugs and Moderna catalystsBreaking BiotechNov 9, 2026 - Nov 6, 2026
Election stakes meet biotech’s regulatory and pipeline risksBiotech HangoutNov 6, 2026 - Nov 6, 2026
Data-center backlash forces markets to rethink AI growthThe Compound and FriendsNov 6, 2026